Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
Lyons KE, Friedman JH, Hermanowicz N, Isaacson SH, Hauser RA, Hersh BP, Silver DE, Tetrud JW, Elmer LW, Parashos SA, Struck LK, Lew MF, Pahwa R.
Lyons KE, et al. Among authors: hauser ra.
Clin Neuropharmacol. 2010 Jan-Feb;33(1):5-10. doi: 10.1097/WNF.0b013e3181b7926f.
Clin Neuropharmacol. 2010.
PMID: 19855267
Clinical Trial.